Clinical trials
Prostate Cancer Screening clinical trials
Below are recruiting prostate cancer screening clinical trials, each written for real people, not researchers. We’re tracking 300 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06915909Recruiting
Robotic prostate surgery with low pressure gas for less pain
This trial tests whether using lower gas pressure during robotic prostate surgery can reduce pain after the operation. It aims to help men recover more comfortably.
Stevenage, HertfordshireAges 18–75 - NCT06616155RecruitingPhase 1/Phase 2
Ruxolitinib and Enzalutamide for Resistant Prostate Cancer
This trial tests two drugs—ruxolitinib and enzalutamide—together to see if they can help men whose prostate cancer has spread and stopped responding to abiraterone. It is for those whose cancer grew quickly on abiraterone.
Chicago, IllinoisAges 18 years+ - NCT06616597RecruitingPhase 2
Targeting gut bacteria to help prostate cancer treatment work again
This trial tests whether adding metronidazole, an antibiotic, can make abiraterone work better in men with metastatic prostate cancer whose PSA is rising despite treatment. It aims to target gut bacteria that may be fueling resistance to the therapy.
Baltimore, MarylandAges 18 years+ - NCT06636526Recruiting
Testing a new prostate cancer blood test in diverse groups
This study tests a new blood test (PRODICT®) to see how well it works for finding prostate cancer in men from different ethnic backgrounds. It aims to make sure the test is accurate and fair for everyone.
Sutton, SurreyAges 40–55 - NCT06636682RecruitingPhase 2
Vaccine for men with high-risk prostate cancer after surgery
This trial tests a personalized vaccine (FK-PC101) given after prostate removal surgery for men with high-risk prostate cancer. It aims to see if the vaccine can help prevent the cancer from coming back without the need for additional hormone therapy or radiation.
Chicago, IllinoisAges Any age - NCT06673329RecruitingPhase 1
Brodalumab for immune-related side effects from cancer treatment
This trial tests if brodalumab, an antibody that blocks a specific immune pathway (IL-17), can help control side effects caused by immunotherapy cancer treatment. It is for people with advanced solid organ cancers who have immune-related side effects that are suspected to involve IL-17.
New York, New YorkAges 18 years+ - NCT06738303RecruitingPhase 2
Comparing chemo vs lutetium therapy for advanced prostate cancer
This trial compares two treatment approaches for men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy. One option is chemotherapy (cabazitaxel with or without carboplatin) and the other is a radioactive drug (177Lu-PSMA-617) that targets cancer cells. The study looks at which works better and for whom.
Cleveland, OhioAges 19 years+ - NCT06785636RecruitingPhase 1/Phase 2
New drug combination for advanced prostate cancer
This study tests a new drug (pocenbrodib) alone or combined with another hormone therapy (darolutamide) for men with advanced prostate cancer that has spread. It is for those who have already tried Pluvicto and one other hormone therapy, but not yet chemotherapy.
Fountain Valley, CaliforniaAges 18 years+ - NCT06940271Recruiting
Nerve wrapping with donor tissue during prostate cancer surgery study
This study tests whether wrapping nerves with a special donated tissue during prostate removal surgery helps keep erectile function and urinary control. It may help men with localized prostate cancer who have good erections now and want to preserve sexual function after surgery.
Jacksonville, FloridaAges 45 years+ - NCT06970119RecruitingPhase 1/Phase 2
Study of INR102 for advanced prostate cancer (Phase 1/2)
This trial tests a new investigational drug called INR102 for prostate cancer that has spread and stopped responding to standard treatments. It's given by injection, and the study will check if it's safe and if it can shrink or slow the cancer.
Wuxi, JiangsuAges 18 years+ - NCT06972628RecruitingPhase 2
177Lu-PSMA-617 for advanced prostate cancer with bone spread
This trial tests a radioactive drug called 177Lu-PSMA-617 to see if it can help men with metastatic castration-resistant prostate cancer that has spread to the bones in a specific pattern (superscan). It's for patients who have already tried hormone therapy and have PSMA-positive tumors.
Houston, TexasAges 18 years+ - NCT07001709RecruitingPhase 4
How abiraterone affects oxycodone in prostate cancer
This study looks at how a common prostate cancer drug (abiraterone) affects how the body processes a painkiller (oxycodone). Men with prostate cancer who take abiraterone will be compared with those who do not, to see if the painkiller works differently.
Deventer, OverijsselAges 18 years+ - NCT07008781Recruiting
Student-led program to boost cancer screening in families
This study tests whether a program led by students can help more families get cancer screenings. If you are a high school student and have an adult family member who needs a screening, you may be able to join together.
New Brunswick, New JerseyAges 15–80 - NCT07027124RecruitingPhase 2
High-risk prostate cancer treatment before and after surgery
This trial tests a combination of hormone therapy, a targeted pill (Darolutamide), and an immunotherapy drug (Pembrolizumab) before and after surgery for men with high-risk prostate cancer that has specific genetic features. The goal is to see if this approach helps prevent the cancer from coming back.
New York, New YorkAges 18 years+ - NCT07055165Recruiting
Prostate cancer education and screening for Black men
This trial offers free prostate cancer education and screening to Black men in Oklahoma who haven't been diagnosed yet. It aims to increase awareness and catch cancer early, but requires using a phone app for 30 days.
Oklahoma City, OklahomaAges 45–69 - NCT07073794RecruitingPhase 2
Home versus clinic cancer therapy for Black men with prostate cancer
This study looks at whether giving certain prostate cancer treatments at home (instead of the clinic) works as well for Black men. If you qualify, you may get your regular treatment at home with a nurse.
Jacksonville, FloridaAges 18 years+ - NCT07090148RecruitingPhase 1
Vaccine plus immunotherapy for prostate cancer that has returned
This trial tests a combination of a DNA vaccine (pTVG-HP) and an immunotherapy drug (nivolumab) along with targeted radiation or ablation of remaining cancer spots. It is for men whose prostate cancer has come back after surgery but hasn't spread widely.
Madison, WisconsinAges 18 years+ - NCT07103018RecruitingPhase 1
Study of KTX-2001 for men with advanced prostate cancer
This trial tests a new drug called KTX-2001, possibly combined with another drug (darolutamide), for men whose prostate cancer has spread and stopped responding to standard hormone treatments. The goal is to see if it can help shrink tumors or slow the cancer's growth.
San Francisco, CaliforniaAges 18 years+ - NCT07109427Recruiting
Prostate cancer screening alert study
This trial tests whether an alert in your electronic health record helps more people get PSA screening for prostate cancer. If you are a man at average or high risk, this study may help ensure you are screened appropriately.
St Louis, MissouriAges 40–75 - NCT07111507RecruitingPhase 2
Tarlatamab for advanced prostate cancer
This trial tests a drug called tarlatamab for people with advanced prostate cancer that has a specific protein (DLL3) on their tumor cells. The goal is to see if tarlatamab can help shrink or slow the cancer.
San Diego, CaliforniaAges 18 years+ - NCT07115914Recruiting
PSMA PET scan to monitor prostate cancer after focal therapy
This trial uses a special PET scan (PSMA PET) to check if prostate cancer returns after focused treatment (focal therapy). It may help find any remaining cancer that standard scans miss.
Chicago, IllinoisAges 18 years+ - NCT07145177RecruitingPhase 1
Lu177-PSMA with liver treatment for advanced prostate cancer
This trial tests a targeted radiation drug (Lu177-PSMA) combined with procedures that treat liver tumors directly (like ablation or radiation). It is for men with prostate cancer that has spread to the liver and is no longer responding to hormone therapy. The goal is to see if this combination works better together.
San Francisco, CaliforniaAges 18 years+ - NCT07145255RecruitingPhase 1/Phase 2
Study of MBRC-201 for advanced solid tumors
This trial tests a new drug, MBRC-201, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if it helps shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT07179783RecruitingPhase 2
Sacituzumab Tirumotecan and Tagitanlimab for aggressive prostate cancer
This trial tests a combination of two drugs for men with aggressive or neuroendocrine prostate cancer that has worsened after previous hormone therapy. The goal is to see if the combination can shrink tumors or slow the disease.
Tianjin, Tianjin MunicipalityAges 18 years+
Hear when a new Prostate Cancer Screening trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer screening?
- Yes. Clin2 currently lists 300 recruiting prostate cancer screening studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer screening trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer screening trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.